Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXEO Lexeo Therapeutics	$4.90 +2.5%	$4.38	$1.45 ▼ $12.37	$264.60M	1.36	392,470 shs	519,073 shs
RLAY Relay Therapeutics	$3.69 +8.2%	$3.49	$1.77 ▼ $10.72	$636.20M	1.62	2.11 million shs	1.11 million shs
SIGA Siga Technologies	$9.13 +4.3%	$7.21	$4.95 ▼ $9.80	$653.76M	0.94	628,632 shs	861,154 shs
TERN Terns Pharmaceuticals	$6.93 +2.5%	$5.27	$1.87 ▼ $11.40	$606.45M	-0.05	1.15 million shs	1.30 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXEO Lexeo Therapeutics	0.00%	+3.81%	+33.51%	+73.76%	-61.39%
RLAY Relay Therapeutics	0.00%	+4.24%	+0.27%	+26.80%	-50.27%
SIGA Siga Technologies	0.00%	+7.41%	+29.32%	+54.48%	-7.03%
TERN Terns Pharmaceuticals	0.00%	-1.70%	+14.36%	+129.47%	-12.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LXEO Lexeo Therapeutics	2.3498 of 5 stars	3.5	1.0	0.0	2.1	2.5	0.6
RLAY Relay Therapeutics	1.8228 of 5 stars	3.5	0.0	0.0	1.5	2.5	0.6
SIGA Siga Technologies	2.1058 of 5 stars	0.0	2.0	0.0	2.6	0.8	3.1
TERN Terns Pharmaceuticals	3.7602 of 5 stars	3.3	1.0	4.1	1.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXEO Lexeo Therapeutics	3.00	Buy	$15.33	212.93% Upside
RLAY Relay Therapeutics	2.92	Moderate Buy	$17.25	367.48% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	125.47% Upside

Current Analyst Ratings Breakdown

Latest LXEO, TERN, RLAY, and SIGA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $15.00
8/15/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $9.00
8/8/2025	RLAY Relay Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $19.00
7/31/2025	LXEO Lexeo Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXEO Lexeo Therapeutics	$650K	407.08	N/A	N/A	$2.56 per share	1.91
RLAY Relay Therapeutics	$10.01M	63.56	N/A	N/A	$3.86 per share	0.96
SIGA Siga Technologies	$138.72M	4.71	$0.84 per share	10.91	$2.92 per share	3.13
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$3.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXEO Lexeo Therapeutics	-$98.33M	-$3.26	N/A	N/A	N/A	N/A	-94.65%	-73.36%	N/A
RLAY Relay Therapeutics	-$337.71M	-$1.95	N/A	N/A	N/A	N/A	-41.49%	-37.43%	11/5/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$1.13	8.08	7.30	N/A	45.73%	40.52%	35.62%	11/6/2025 (Estimated)
TERN Terns Pharmaceuticals	-$88.85M	-$1.04	N/A	N/A	N/A	N/A	-27.35%	-26.18%	11/11/2025 (Estimated)

Latest LXEO, TERN, RLAY, and SIGA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	LXEO Lexeo Therapeutics	-$0.64	-$0.60	+$0.04	-$0.60	N/A	N/A
8/7/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	-$0.41	+$0.08	-$0.41	$0.07 million	$0.70 million
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million
8/5/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXEO Lexeo Therapeutics	N/A	4.43	3.42
RLAY Relay Therapeutics	N/A	20.92	20.92
SIGA Siga Technologies	N/A	10.09	8.52
TERN Terns Pharmaceuticals	N/A	24.70	24.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LXEO Lexeo Therapeutics	60.67%
RLAY Relay Therapeutics	96.98%
SIGA Siga Technologies	55.40%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
LXEO Lexeo Therapeutics	5.30%
RLAY Relay Therapeutics	4.87%
SIGA Siga Technologies	1.95%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LXEO Lexeo Therapeutics	58	54.00 million	51.14 million	Not Optionable
RLAY Relay Therapeutics	330	172.41 million	164.02 million	Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable
TERN Terns Pharmaceuticals	40	87.51 million	86.20 million	Not Optionable

LXEO, TERN, RLAY, and SIGA Headlines

Recent News About These Companies

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

August 21 at 4:05 PM | globenewswire.com

Disappointing competitor oral GLP-1 data an opportunity for Terns, says Mizuho

August 20, 2025 | msn.com

5 Oral Obesity Drugs Challenging Lilly’s Orforglipron

August 12, 2025 | biospace.comB

William Blair Has Positive Outlook of TERN FY2025 Earnings

August 9, 2025 | marketbeat.com

Terns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

August 6, 2025 | marketbeat.com

Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market

August 6, 2025 | biospace.comB

Terns to stop funding metabolic disease trials beyond 2025, seeks partners for assets

August 6, 2025 | fiercebiotech.comF

Terns (TERN) Q2 Net Loss Narrows 16%

August 6, 2025 | fool.com

Terns Pharmaceuticals Reports Q2 2025 Financial Results

August 6, 2025 | tipranks.com

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 5, 2025 | globenewswire.com

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

August 4, 2025 | globenewswire.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 3, 2025 | marketbeat.com

Terns Pharmaceuticals (TERN) to Release Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Obesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-Waiting

July 14, 2025 | biospace.comB

Terns Pharmaceuticals CEO & Director Acquires 98% More Stock

July 4, 2025 | finance.yahoo.com

Terns pharmaceuticals CEO Burroughs buys $90k in shares

June 27, 2025 | investing.com

Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

June 26, 2025 | fiercebiotech.comF

Terns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - Nasdaq

June 24, 2025 | nasdaq.com

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - Morningstar

June 24, 2025 | morningstar.comM

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

June 23, 2025 | medpagetoday.comM

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

June 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LXEO, TERN, RLAY, and SIGA Company Descriptions

Lexeo Therapeutics NASDAQ:LXEO

$4.90 +0.12 (+2.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.90 +0.00 (+0.02%)

As of 08/22/2025 07:56 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Relay Therapeutics NASDAQ:RLAY

$3.69 +0.28 (+8.21%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.68 0.00 (-0.14%)

As of 08/22/2025 06:26 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Siga Technologies NASDAQ:SIGA

$9.13 +0.38 (+4.34%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.01 -0.13 (-1.37%)

As of 08/22/2025 07:47 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Terns Pharmaceuticals NASDAQ:TERN

$6.93 +0.17 (+2.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.06 +0.13 (+1.86%)

As of 08/22/2025 07:55 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time